Zolgensma Approved to Treat Young SMA Patients in Canada
Jan 22, 2021, 12:00 AM
Share
Subscribe
SMA News Today’s multimedia associate, Price Wooldridge, discusses a Spinraza Phase 4 trial to treat children who failed to respond to gene therapy.
DeAnn Runge shares her experience obtaining her first dose of the Pfizer COVID vaccine.
Are you interested in learning more about spinal muscular atrophy? If so, please visit https://smanewstoday.com/